コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Antitumour activity was assessed in post-platinum patients who received at least one dose of avelumab.
3 The primary endpoint was assessed in all patients who received at least one dose of combination therap
4 se stomatitis by 8 weeks assessed in the full analysis set (patients who received at least one dose of everolimus and exe
5 tolerability were assessed in the safety analysis set (all patients who received at least one dose of gilteritinib).
8 The primary endpoint was assessed in patients who received at least one dose of MABp1 or placebo (
9 Activity and safety were analysed in all patients who received at least one dose of pembrolizumab (all
10 We assessed efficacy and safety in all patients who received at least one dose of study drug (intent
12 ion-to-treat population, whereas safety was analysed in all patients who received at least one dose of study drug and had
14 Responses were assessed in the full analysis set (all patients who received at least one dose of study drug and who
17 from the stomach), measured at 5 weeks and 16 weeks in all patients who received at least one dose of study drug, with m
21 full analysis set, which consisted of all randomly assigned patients who received at least one dose of study drug.
23 y intention to treat and the safety population included all patients who received at least one dose of study drug.
24 was by intention to treat, and safety analysis included all patients who received at least one dose of study drug.
27 -Revised) and overall survival, analysed at 48 weeks in all patients who received at least one dose of study drug.
29 SVR12; the primary endpoint and safety were assessed in all patients who received at least one dose of study drugs.
30 ), and the safety population included 543 randomly assigned patients who received at least one dose of study medication.
33 The key exploratory PRO endpoints (analysed for all patients who received at least one dose of study treatment an
34 efficacy was assessed in the intention-to-treat population (patients who received at least one dose of study treatment an
35 were done in the treated population (all randomly assigned patients who received at least one dose of study treatment).
36 In the safety population containing patients who received at least one dose of study treatment, a
37 e intention-to-treat population; safety was analysed in all patients who received at least one dose of study treatment, w
38 ntention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment.
39 the intention-to-treat population; safety analyses included patients who received at least one dose of study treatment.
40 SCT) and after study treatment and subsequent HSCT, for all patients who received at least one dose of study treatment.
41 ntion-to-treat population) and the safety analysis included patients who received at least one dose of study treatment.
44 mly assigned to treatment; safety analyses were done in all patients who received at least one dose of the study drug.
45 y were analysed in the safety population, consisting of all patients who received at least one dose of their randomised t
47 ssessed in the intention-to-treat populations and safety in patients who received at least one dose of treatment.
50 otocol for all patients who commenced drug and included all patients who received at least one dose of venetoclax.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。